Trials / NCT00661479
An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa
Completed Phase 1 / Phase 2 Drug / neuroprotection
- Sponsor
- Allergan
- Treatment
- 400 µg Brimonidine Tartrate Implant; 200 µg Brimonidine Tartrate Implant; 100 µg Brimonidine Tartrate Implant; Sham (no implant)
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to no upper limit
- Enrollment
- 21 participants
- Started
- 2008-07
- Main results expected
- 2009-12
- Results posted
- Yes
- Record last updated
- 2013-04-24
What the study is testing
This exploratory, 12-month, ascending-dose study will evaluate the safety and effects on visual function of a single injection of Brimonidine intravitreal implant in one eye of patients with Retinitis Pigmentosa.
Where it runs
France (1)
- , Paris
Germany (1)
- , Tübingen
Portugal (1)
- , Coimbra
United States (1)
- , Arlington, Texas